Using in vivo-biotinylated ubiquitin to describe a mitotic exit ubiquitome from human cells by Min, M. et al.
 
Repository of the Max Delbrück Center for Molecular Medicine (MDC) 
in the Helmholtz Association  
 
http://edoc.mdc-berlin.de/14260  
 
 
 
 
 
Using in vivo-biotinylated ubiquitin to describe a mitotic exit ubiquitome 
from human cells 
 
Min, M. and Mayor, U. and Dittmar, G. and Lindon, C. 
 
 
 
 
 
This is a copy of the original article. 
 
This research was originally published in Molecular & Cellular Proteomics. Min, M. and Mayor, U. 
and Dittmar, G. and Lindon, C. Using in vivo-biotinylated ubiquitin to describe a mitotic exit 
ubiquitome from human cells. Mol Cell Proteomics. 2014; 13: 2411-2425. © 2014 by The American 
Society for Biochemistry and Molecular Biology, Inc. 
 
 
 
Molecular & Cellular Proteomics 
2014 SEP 01 ; 13(9): 2411-2425 
Doi: 10.1074/mcp.M113.033498  
 
American Society for Biochemistry and Molecular Biology 
Using in Vivo Biotinylated Ubiquitin to Describe
a Mitotic Exit Ubiquitome from Human Cells*□S
Mingwei Min‡, Ugo Mayor§¶, Gunnar Dittmar, and Catherine Lindon‡**
Mitotic division requires highly regulated morphological
and biochemical changes to the cell. Upon commitment
to exit mitosis, cells begin to remove mitotic regulators in
a temporally and spatially controlled manner to bring
about the changes that reestablish interphase. Ubiquitin-
dependent pathways target these regulators to generate
polyubiquitin-tagged substrates for degradation by the
26S proteasome. However, the lack of cell-based assays
to investigate in vivo ubiquitination limits our knowledge
of the identity of substrates of ubiquitin-mediated regula-
tion in mitosis. Here we report an in vivo ubiquitin tagging
system used in human cells that allows efficient purifica-
tion of ubiquitin conjugates from synchronized cell popu-
lations. Coupling purification with mass spectrometry, we
have identified a series of mitotic regulators targeted for
polyubiquitination in mitotic exit. We show that some are
new substrates of the anaphase-promoting complex/
cyclosome and validate KIFC1 and RacGAP1/Cyk4 as
two such targets involved respectively in timely mitotic
spindle disassembly and cell spreading. We conclude
that in vivo biotin tagging of ubiquitin can provide valu-
able information about the role of ubiquitin-mediated
regulation in processes required for rebuilding inter-
phase cells. Molecular & Cellular Proteomics 13:
10.1074/mcp.M113.033498, 2411–2425, 2014.
Ubiquitination has emerged as a major post-translational
modification determining the fate of cellular proteins. One of
these fates is proteolysis, whereby the assembly of polyubiq-
uitin chains creates signatures on target proteins that specify
delivery to the 26S proteasome for proteolytic destruction.
Targeted proteolysis is critical to the control of cell division.
For example, the universally conserved mechanism of mitotic
exit depends upon rapid proteolysis of mitotic cyclins and
securins to drive the transition frommitosis to interphase. This
transition is under surveillance by the spindle assembly
checkpoint (SAC),1 which controls the activity of a multi-
subunit ubiquitin ligase, the anaphase-promoting complex/
cyclosome (APC/C) (1, 2).
Much of the known specificity in the ubiquitin-proteasome
system (UPS) is mediated at the level of substrate targeting by
ubiquitin ligase (E3) enzymes, of which there are more than
600 in human cells. Given these facts, it is perhaps surprising
that the APC/C is almost the only known engineer of the
protein landscape after anaphase onset, targeting mitotic reg-
ulators for destruction with high temporal specificity (2–4).
Some roles for nondegradative ubiquitination in regulating the
localization of mitotic kinases Aurora B and Plk1 have been
described (5–9), and a growing list of reported ubiquitin inter-
actors can modulate ubiquitin-dependent events during mito-
sis (10). However, the majority of ubiquitination events that
have so far been described as occurring at the transition from
mitosis to interphase are APC/C-dependent.
Two co-activator subunits, Cdc20 and Cdh1, play vital roles
in APC/C-dependent substrate recognition (11) by recogniz-
ing two widely characterized degrons, the D-box and the KEN
motif (12, 13). Computational approaches that have been
used to calculate the total number of APC/C substrates from
the prevalence of degrons in the human proteome estimate
that there are between 100 and 200 substrates (14), and
experiments using in vitro ubiquitination of protein arrays have
given rise to estimates in the same range (15). Most of the
mitotic regulators targeted by the APC/C during mitotic exit in
human cells have been identified via in vitro degradation
assays or ubiquitination assays on in vitro–expressed pools of
substrates (15–18). These approaches have identified several
important substrates, but in the absence of in vivo parameters
they may not identify substrates whose targeting depends on
post-translational modifications or substrates that are only
recognized in vivo as components of higher-order complexes.
Not all substrates identified in this way have been validated as
polyubiquitinated proteins in vivo. Multiple recent proteomic
studies have identified large numbers of in vivo ubiquitin-
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modified sites from yeast (19–21) and human cells (22–29).
None of these studies have used synchronized cell popula-
tions to provide information on the timing or regulation of
substrate ubiquitination.
We reasoned that a better view of ubiquitin-mediated pro-
cesses that regulate mitotic exit would come from identifying
proteins that are ubiquitinated in vivo during mitotic exit. With
this goal in mind we adopted a system for in vivo tagging of
ubiquitin chains with biotin, previously used to identify ubiq-
uitin-conjugated proteins from the Drosophila neural system
(30), and applied it to a human cell line (U2OS) that can be
tightly synchronized at mitosis. In contrast to several recent
studies that employed antibodies specific to the diGly-Lys
remnant that marks ubiquitination sites following trypsin di-
gestion (19, 25), an in vivo ubiquitin tagging strategy allows
direct validation of candidate ubiquitinated proteins (whether
mono- or polyubiquitinated) through immunoblotting of sam-
ples. Moreover, in contrast to other methods for affinity tag-
ging of ubiquitin, or affinity purification via ubiquitin-binding
domains, the use of the biotin tag enables purification under
highly denaturing conditions for stringent isolation of ubiqui-
tin-conjugated material from higher eukaryotes. His6-tagged
ubiquitin is also available for use under denaturing conditions,
but it is not generally useful in higher eukaryotic cells, where
a high frequency of proteins containing multiple histidine res-
idues confounds the specificity of nickel-affinity pulldowns (as
discussed in detail in Ref. 30). Therefore, in this paper we
describe the reproducible identification and validation of mi-
toticphase-specific polyubiquitinated proteins via the in vivo
biotinylation of ubiquitin. A large number of polyubiquitinated
proteins that we identified are specific to mitotic exit, when
the APC/C is active, and we expect that many of them are
substrates for the APC/C. We formally identified KIFC1/HSET
and Cyk4/RACGAP1 as targets of APC/C-dependent ubiqui-
tin-mediated proteolysis after anaphase onset and investi-
gated the role of their ubiquitination in the regulation of mitotic
exit. Cell cycle phase-specific information on protein ubiquiti-
nation and the generation of ubiquitinated protein networks
provides a framework for further investigation of ubiquitin-
controlled processes occurring during the rebuilding of inter-
phase cells.
EXPERIMENTAL PROCEDURES
Plasmids and siRNA—bioUb6-BirA and BirA sequences (30) were
inserted in pTRE-tight vector (Invitrogen) to generate pTRE-bioUb6-
BirA and pTRE-BirA plasmids. Venus was swapped for fluorescent
proteins in pEYFP-N1-Aurora A (31) to make pVenus-N1-Aurora A.
Human RacGAP1 cDNA (a kind gift from Masanori Mishima) was
inserted into pVenus-C1. Human KIFC1 cDNA (a kind gift from Paola
Coelho) was inserted into pVenus-N1. K292R, F289G, and C ver-
sions of RacGAP1 and the R5A,L8A version of KIFC1 were generated
using standard mutagenesis techniques. Full cloning details are avail-
able upon request. mCherry-MKLP1 was a gift from Masanori
Mishima. siRNA sequences targeting APC3, Cdh1, and RacGAP1
3UTR were as previously described (31, 32). Plasmids and siRNAs
were electroporated into cells using the Neonx transfection system
(Invitrogen).
Cell Culture and Synchronization—U2OS tet-OFF cells were cul-
tured in high-glucose DMEM (Invitrogen). Cell culture medium was
supplemented with FBS (10%), penicillin-streptomycin, amphotericin
B, 500 g/ml geneticin (all from PAA Laboratories, Pasching, Austria),
and 1 g/ml tetracycline hydrochloride (Calbiochem). U2OS-bioUb cells
and U2OS-BirA cells were obtained via clonal selection with 170 g/ml
Hygromycin B (Calbiochem) after transfection of U2OS tet-OFF cells
with pTRE-bioUb6-BirA or pTRE-BirA in a ratio of 10:1 with pCMVhygro
and were supplied with 5 M biotin in culture. The hTERT-RPE1 (RPE)
cell line stably expressing -actinin-Venus was described previously
(33). Cells were synchronized to prometaphase by sequential blocks
with 25 mM thymidine and 10 M S-trityl-L-cysteine (STLC, Tocris Bio-
science, Bristol, UK) for 20 h and 16 h, respectively, and collected via
mitotic shake-off. Mitotic exit cells were obtained through treatment
with 10 M Aurora B inhibitor ZM447439 (ZM) (Tocris Bioscience) or 300
nM CDK I/II inhibitor III (Calbiochem) for the indicated time.
Purification of in Vivo–ubiquitinated Material—For each sample,
about 3 108 cells were lysed in 10 ml lysis buffer (8 M urea, 1% (v/v)
SDS, 1 EDTA-free protease inhibitor mixture (Roche), 50 mM N-
ethylmaleimide (Sigma) in 1 PBS). The lysate was then diluted with
17.5 ml dilution buffer (1.43 M NaCl, 1 EDTA-free protease inhibitor
mixture, 50 mM N-ethylmaleimide in 1 PBS) and applied to 1 ml High
Capacity NeutrAvidin Agarose Resin (Thermo Scientific) in a binding
step incubated on rollers for 1 h at room temperature and 2 h at 4 °C.
The beads were washed as described in Ref. 30. Material on beads
was eluted in 4 Laemmli buffer  100 mM DTT (95 °C, 10 min) for
immunoblotting, or else processed directly for mass spectrometry.
Mass Spectrometry—The proteins were converted to peptides us-
ing a two-step digestion protocol adapted from de Godoy et al. (34).
The peptides were separated on a 15-cm reverse phase column
(packed in-house with 3-m Reprosil beads (Dr. Maisch GmbH,
Ammerbuch, Germany)) using a 5% to 50% acetonitrile gradient
(Proxeon nano LC, Thermo Scientific). The peptides were ionized on
a Proxeon ion source and sprayed directly into the mass spectrom-
eter (Q-Exactive or Velos-Orbitrap, Thermo Scientific). The recorded
spectra were analyzed using the MaxQuant software package (ver-
sion 1.3.0.5) with a 1% false discovery rate for both peptides and
proteins (35). Searches were performed using the Andromeda search
engine against an IPI human database (version 3.84, 90,166 entries).
Cysteine carbamidomethylation was selected as fixed modification,
and methionine oxidation, protein N-terminal acetylation, and glygly-
lysine were allowed as variable modifications. Two missed trypsin (full
specificity) cleavages were allowed. The mass tolerance of precursor
ions was set at 6 ppm, and for fragment ions it was 20 ppm. The raw
data associated with this study can be found at the Proteomics DB
repository (https://www.proteomicsdb.org/) with project I.D. 4156.
Annotated spectra from single peptide identifications can be viewed
online as supplemental data.
Gene Ontology Enrichment Analysis—p values of Gene Ontology
(GO) enrichments in each dataset of protein hits were determined
using g:Profiler (36). The GO terms were filtered according to the
following attributes: (a) the p value in at least one protein-hit dataset
was less than 103, (b) the GO term belonged to “cellular processes,”
and (c) the depth of the GO term was less than 10. The significance
of enrichment was presented as a heat map using the R environment
(37) and the gplots package (38).
Imaging—Cells were seeded after electroporation onto eight-well
plastic-bottom slides (Ibidi GmbH, München, Germany) at a density of
2  104 cells/cm2. The imaging medium was L-15 supplemented with
FBS and antibiotics as described above. All time-lapse imaging was
carried out on an Olympus CellR imaging platform comprising an
Olympus IX81 motorized inverted microscope, an Orca-CCD camera
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(Hamamatsu Photonics), a motorized stage (Prior Scientific, Cam-
bridge, UK), and a 37 °C incubation chamber (Solent Scientific, Se-
gensworth, UK). Cells were imaged via epifluorescence and differen-
tial interference contrast (DIC) microscopy using a 40 1.3 numerical
aperture oil objective. Movies were recorded using Olympus CellR
software, acquiring data from up to 20 fields per experiment at 2-min
intervals and with no binning. Image sequences were exported as
12-bit TIFF files for analysis in ImageJ. For quantification of Venus
levels in single cell degradation assays, fluorescence was measured
as pixel values within a region of interest (ROI) selected to include the
entire cell when applied to all images in a series, and from which
background pixel values were subtracted. DIC images were used to
determine the onset of anaphase.
Antibodies—See supplemental Table S4.
RESULTS
Purification of a Mitotic Exit Ubiquitome—Polyubiquitinated
conjugates are typically difficult to isolate in significant quan-
tities. Therefore, we adopted a strategy for proteomic profiling
of ubiquitin conjugates that would allow their isolation from
cell extracts prepared under fully denaturing conditions, using
biotin-avidin affinity purification (the strongest non-covalent in-
teraction known, Kd  10
14 M). Fully denaturing conditions
would preserve polyubiquitin chains and ensure isolation of
ubiquitin-conjugated material only, excluding from our studies
the ubiquitin-binding proteins that can represent a large propor-
tion of hits in studies carried out under native conditions (39, 40).
We further reasoned that highly synchronized cell popula-
tions would be required to identify substrates of the UPS
specific to mitotic exit, so we generated a highly synchroniz-
able human cell line expressing in vivo–biotinylated ubiquitin.
bioUb is generated via expression of a synthetic linear con-
struct of six ubiquitin moieties bearing a short biotinylatable
tag in tandem with the Escherichia coli biotin ligase BirA. Each
ubiquitin has an N-terminal 16-amino-acid tag that can be
recognized and biotinylated by the BirA enzyme (30, 41). We
inserted the bioUb6–BirA construct into human U2OS cells on
a plasmid allowing tight control of expression by tetracycline
(42). After clonal selection we chose a cell line in which the
level of biotinylated ubiquitin was low relative to levels of
endogenous ubiquitin in the cell. Total ubiquitin levels in the
cell were unchanged after induction (Fig. 1A), and measure-
ment of the ratio of bioUb:Ub-modified histone H2A indicated
that less than 10% of ubiquitin in the cell carried the biotiny-
latable tag (supplemental Fig. S1). We expected that a low
bioUb:Ub ratio would minimize potential perturbation of poly-
ubiquitin chain topology and favor the isolation of polyubiq-
uitinated conjugates that incorporate multiple ubiquitins. In-
deed, we found that 50% of high-MW ubiquitin conjugates,
which contain polyubiquitinated proteins, were cleared from
cell extracts by biotin–NeutrAvidin pulldown, whereas the
level of free ubiquitin was hardly perturbed (Fig. 1B). We
confirmed that the in vivo degradation kinetics of a known
APC/C-dependent substrate of the UPS, Aurora A kinase (31),
was unaffected by the induction of bioUb (Fig. 1C). We also
constructed a cell line expressing BirA alone at levels similar
to those of bioUb6-BirA expressed in our
bioUb cells (supple-
mental Fig. S1) to allow us to control for the nonspecific
biotinylation of cellular proteins.
We prepared cells synchronized at mitosis after 40 h of
expression of bioUb using sequential thymidine release/Eg5
inhibitor (STLC) treatment to arrest cells in prometaphase (M
phase population) with monopolar spindles that trigger the
SAC. We then released cells from SAC-mediated arrest
through inhibition of Aurora B kinase activity (using specific
inhibitor ZM) to generate mitotic exit fractions at 30 and 70
min after ZM treatment (Fig. 1D). The 30-min time point (mi-
totic exit I) was that at which we saw extensive ubiquitination
of cyclin B1 (Fig. 1E), and 70 min (mitotic exit II) was the time
point at which we saw extensive ubiquitination of Aurora
kinase (see Fig. 3B). In terms of the morphology of cells
undergoing mitotic exit, these time points correspond to early
and late time points during C-phase, the window of time
during which cells remain competent to complete cytokinesis
(43), and we refer to them respectively as C1 and C2 in Figs.
1–3. We chose a ZM-release protocol over a protocol for the
release of SAC-arrested cells using mitotic cyclin-dependent
kinase (Cdk1) inhibitor treatment, as described elsewhere (44,
45), because the anaphase degradation rate of APC/C sub-
strates that we have tested is reduced when Cdk1 is inhibited
(but not when Aurora B is inhibited), suggesting that the timing
of Cdk1 inactivation during anaphase is critical for optimal
targeting of substrates at this time.2 Our synchronization pro-
tocol gave us highly enriched mitotic exit fractions as evi-
denced by the presence of cyclin B1 conjugates after single-
step pulldown on NeutrAvidin beads. Critically, ubiquitinated
cyclin B1 was recovered only from cells in which the SAC had
been inactivated (Fig. 1E, lanes M* and C1), the condition for
cyclin B1 degradation in vivo (46). Moreover, pulldowns were
highly specific for ubiquitin-modified material, as unmodified
cyclin B1 was undetectable in the pulldown fractions, even
though these were loaded in 400-fold excess relative to the
polyubiquitinated fraction (Fig. 1E). Having validated both the
specificity of our pulldowns and the robustness of our syn-
chronization protocol, we carried out large-scale preparations
of cell extracts from bioUb cells and control BirA cells for
NeutrAvidin pulldown. Silver staining of purified samples
showed a specific enrichment of high-MW material in bioUb
samples relative to BirA control samples, corresponding to
ubiquitin-conjugated proteins (Fig. 1F).
We carried out LC-MS/MS analysis of purified ubiquitin-
conjugated material on an LTQ-Orbitrap mass spectrometer.
Output from M, C1, and C2 pulldowns was searched against
the IPI database for peptides with up to two missed cleavages
and modifications including ubiquitination. A total of 580 pro-
teins were identified, with 470 of these specific to samples
from bioUb cells (Fig. 2A, supplemental Fig. S2, supplemental
Tables S1 and S2). Hits present in the BirA-expressing control
2 C. Lindon, unpublished data.
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FIG. 1. Experimental set-up of mitotic ubiquitome analysis using in vivo biotinylated ubiquitin. A, induction of biotinylated ubiquitin in
bioUb cells. Tetracycline was withdrawn for 48 h. Immunoblots of whole cell extracts prepared under fully denaturing conditions were probed
with antibodies against biotin or ubiquitin conjugates (FK2). Quantification of the ubiquitin blot showed no increase (100 	 1% (S.D.), n 
 3)
in total cellular ubiquitin after induction of bioUb6–BirA. Histone 2A (H2A) was a major ubiquitinated band in these cells. B, efficient pulldown
of cellular ubiquitin conjugates using biotinylated ubiquitin. Immunoblots of cell extracts induced for bioUb expression showed levels of free and
conjugated ubiquitin before and after incubation with NeutrAvidin beads. Even though the ratio of bioUb:ubiquitin in the cell was low,
polyubiquitinated conjugates were efficiently purified from extracts. See also supplemental Note S1 and supplemental Fig. S1. C, induction of
biotinylated ubiquitin did not affect the degradation kinetics of a substrate of mitotic proteolysis. Biotinylated ubiquitin was induced (-tet) or
repressed (tet) following electroporation of bioUb cells with Aurora A-Venus, with parental U2OS cells electroporated as controls. After 40 h
mitotic cells were imaged via fluorescence time-lapse microscopy. Aurora A-Venus levels were quantified and plotted as a function of
anaphase onset. Left, degradation curves for individual cells. Right, degradation averaged for cells under each condition; error bars show
standard deviations. D, synchronization outline. BirA cells (negative control) and bioUb cells were synchronized in prometaphase by sequential
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samples were known endogenous biotinylated proteins (car-
boxylases) and potential contaminants also present in the
bioUb samples, showing that pulldowns from the BirA cell line
were valid technical controls. Among the bioUb-specific hits,
244 proteins were present in both M- and C-phase pulldowns
(non-phase-specific), and 170 proteins were enriched or
found exclusively in mitotic exit phases C1 and C2 (Fig. 2A,
supplemental Table S2, Table I). Two repeats of the experi-
ment gave overlapping datasets of a similar size (supple-
mental Tables S1 and S2, supplemental Fig. S2). Of the
bioUb-specific hits, more than half of the hits from the first
experiment were present in the second experiment, indicat-
ing the high reproducibility of our assay.
The non-phase-specific bioUb dataset showed strong en-
richment for UPS components, evidenced by the overrepre-
sentation of related GO annotations in this set (Fig. 2B), indi-
cating that the mitotic arrest sample was a valid biological
control. Indeed, many of the hits we expected to find in this
dataset were present, in particular ubiquitin processing en-
zymes that carry ubiquitin as thioester conjugates—chiefly
ubiquitin activating enzymes (UBA1, UBA6), multiple ubiquitin
conjugating enzymes (UBEs), and HECT-family ubiquitin li-
gases (supplemental Table S3). Also present in this dataset
were constitutively ubiquitinated substrates such as histones.
The mitotic exit-specific (C-phase) dataset, in comparison,
was enriched with mitosis-related GO terms (Fig. 2B), indicat-
ing that mitotic regulators targeted for ubiquitination were
efficiently purified via this method. Indeed, this dataset con-
tained 15 known substrates of the APC/C. We carried out an
unbiased ranking of the C-phase dataset according to the
degree of enrichment for ubiquitin-conjugated material (Table
I). Of our 14 top-ranked hits, 2 (cyclin B1 and CKAP2) were
previously described substrates of the APC/C, and others
were putative substrates (PRC1, CKAP2L, RacGAP1, KIF11)
or important mitotic regulators that are promising candidate
substrates (KIFC1, Importin 2) (3, 47, 48).
Validation of a Mitotic Exit Ubiquitome—We tested the re-
liability of our datasets by immunoblotting our samples with
antibodies against a variety of hits chosen from both mitotic-
exit-specific and non-phase-specific datasets to test for the
presence of ubiquitin-conjugated material in our bioUb pull-
downs. All of the 14 hits we tested were confirmed ubiquitin-
conjugated proteins in our extracts, 12 candidate UPS sub-
strates and 2 known ubiquitin conjugating enzymes (E2s). Of
the 12 candidate substrates that we tested, 11 were poly-
ubiquitinated, as evidenced by the presence of high-MW ma-
terial in bioUb pulldowns, and just one, histone H3, was
monoubiquitinated only, confirming the preferential purifica-
tion of polyubiquitinated material from dividing bioUb cells
(Figs. 3A and 3B, supplemental Fig. S3). All of the polyubiq-
uitinated proteins chosen from the mitotic-exit-specific da-
taset (KIF11 (Eg5), TPX2, AURKA, KIFC1, RacGAP1 (Cyk4),
and LMNB2 (Lamin B2)) showed mitotic-exit-specific or
-increased ubiquitination (Fig. 3B, supplemental Fig. S3),
whereas the proteins chosen from the non-phase-specific
dataset, Cdc20, PSMC5 (ATPase of the proteasome 19S
regulatory particle), spartin, and NPM1 (nucleophosmin),
showed ubiquitination throughout mitosis (Fig. 3A, supple-
mental Fig. S3), in line with our classification of hits according
to the peptide numbers observed via mass spectrometry
(supplemental Table S2). Our classification was also consis-
tent with the expected ubiquitination pattern of known sub-
strates of mitotic proteolysis that appeared in our lists of hits
(anillin, AURKA, AURKB, BUB1, cyclin B1, Cdc20, CKAP2,
GTSE1/B99, KIF2C/MCAK, NUSAP1, PLK1, TPX2, TK1) or of
homologues of known APC/C substrates in budding yeast
(KIF11/Eg5, PRC1/Ase1) (3). We detected a small fraction of
UBE2C as a polyubiquitinated protein in our C2 sample (Fig.
3C), consistent with its reported targeting for degradation in
G1 phase (49, 50). However, most of the signal detected for
the two E2s we validated by immunoblotting migrated in the
gel at the same MW as the unmodified E2, consistent with
purification via a thioester ubiquitin linkage disrupted under
the reducing elution conditions used (Fig. 3C). Therefore the
identified E2 enzymes (supplemental Table S3) were more
likely purified through being charged with ubiquitin for conju-
gating to substrates, rather than as substrates themselves of
the UPS.
In conclusion, our validated ubiquitome consists of a mix-
ture of ubiquitinated proteins and ubiquitin-conjugated en-
zymes, and we predict that the majority of non-UPS hits in our
mitotic-exit-specific dataset are novel polyubiquitinated sub-
strates during mitotic exit.
KIFC1 and RacGAP1 Are Substrates of the APC/C at Ana-
phase Onset—We selected two of our top-ranked mitotic-
exit-specific hits, KIFC1 and RacGAP1 (Table I), for further
analysis. KIFC1/HSET (Kinesin-14 family) is a minus-end di-
rected microtubule (MT) motor that contributes to mitotic
spindle assembly, sliding parallel MTs to regulate spindle
length (51) and acting to focus the minus ends of MTs at the
spindle poles. Cancer cells that have multiple centrosomes
depend on KIFC1 to cluster centrosomes in bipolar spindle
thymidine/STLC block, collected by means of mitotic shake-off, and split into three aliquots. One aliquot was harvested under mitotic arrest
(bioUBM sample, also called M phase). The other two aliquots were released from prometaphase block into mitotic exit for 30 min and 70 min
before harvesting (bioUB30 and bioUB70 samples, also referred to as C1 and C2 phases). ZM, 10 M ZM447439. E, immunoblotted extracts
and NeutrAvidin pulldowns from cells synchronized as in D but released from prometaphase block for 15 min (metaphase, M*) or 30 min (C1
phase) were probed with anti-cyclin B1 antibody to reveal specific pulldown of ubiquitinated cyclin B1 from samples in which the SAC was
inactivated. F, silver stain of 1/160 of the purified protein from large-scale preparations of bioUb cells and control BirA cells, showing clear
enrichment of high-MW material in pulldowns from bioUb cells.
A Mitotic Exit Ubiquitome
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formation (52, 53). During mitotic exit, KIFC1 has been shown
to contribute to organization of the central spindle (54). It has
not previously been described as a substrate of mitotic pro-
teolysis. The GTPase activating protein RacGAP1, also known
as MgcRACGAP or hsCYK4, is present in mitotic cells as a
hetero-tetrameric complex known as centralspindlin, together
with the kinesin-6 family member KIF23/MKLP1. Centralspin-
dlin is recruited to and stabilizes the midzone of the anaphase
spindle, where it serves as a critical regulator of cytokinesis
and a major component of the compacted midbody after
furrow ingression (55). RacGAP1 was previously reported as a
putative APC/C substrate (48).
We tested for mitotic-exit-specific destruction of KIFC1 and
RacGAP1 in vivo in single cell assays in which the quantifica-
tion of Venus-tagged proteins could provide readout for sub-
strate proteolysis. We found that both of these targets of
mitotic-exit-specific ubiquitination underwent proteolysis dur-
ing exit from unperturbed bipolar mitosis. KIFC1-Venus deg-
radation started immediately and rapidly at anaphase onset,
with a t1/2 of 35 	 7 min (Fig. 4A). This degradation was
entirely dependent on the presence of a D-box-like motif
(R5SPL) in the unstructured N terminus of KIFC1, indicating
that KIFC1 was probably a substrate of the APC/C. Venus-
RacGAP1 disappeared from cells more slowly, with a t1/2 of
65 	 5 min (Fig. 4B). We confirmed that the disappearance of
Venus-RacGAP1 was proteolysis-dependent, as it did not
occur in the presence of proteasome inhibitor MG132. How-
ever, although RacGAP1 contains five RxxL motifs, none are
good candidates for a D-box (only one is present in an un-
structured region, and mutation of this motif did not abrogate
degradation (56)). Because Venus-RacGAP1 proteolysis was
rather slow in this assay despite its high ranking in our screen
for ubiquitinated proteins, we confirmed that proteolysis of
Venus-RacGAP1 under the conditions used for our screen of
endogenous substrates—that is, during monopolar cytokine-
sis or after treatment with ZM—was not significantly different
from that seen in unperturbed bipolar mitosis (supplemental
Fig. S4).
Next, we tested whether proteolysis of these novel mitotic
substrates depends on APC/C activity. We examined levels of
endogenous KIFC1 and RacGAP1 in synchronized cell ex-
tracts after siRNA-mediated depletion of APC3 or Cdh1 (Fig.
4C). We found that the disappearance of both during mitotic
exit was sensitive to APC3 siRNA but not to Cdh1 siRNA (like
Cyclin B1 but unlike Cdh1-dependent substrate Aurora A
(31)). We also examined the ubiquitination of these substrates
FIG. 2. Identification of a mitotic ubiquitome. A, Venn diagram of hits identified from mitotic fractions. Hits were classified as follows,
according to the peptide numbers present in each sample (classification using label-free quantification data gave very similar results; raw
peptide numbers and intensities are in supplemental Table S1): 470 bioUb-specific hits were categorized as those either absent from the BirA
sample or represented by at least 5-fold more peptides in the bioUb sample. 110 hits below the 5-fold threshold were classified as nonspecific.
bioUb hits were further divided into mitotic-exit-specific (C-phase-specific), prometaphase-specific (M-phase-specific), and non-phase-specific
groups. 170 mitotic-exit-specific hits were assigned as those either absent from the M phase sample or represented by at least 3-fold more
peptides in either of the mitotic-exit-specific samples (C1, C2). 56 prometaphase-specific hits were those present only in the M phase sample
or represented by at least 3-fold more peptides. 244 hits falling under these thresholds were categorized as non-phase-specific. Protein names
in the corresponding categories are shown as word clouds with words sized according to the posterior error probability score of each hit across
samples. A threshold of 1E-5 was applied to remove the low-scoring hits. See supplemental Fig. S2 for full word clouds and supplemental Table
S2 for listed classified hits. B, Gene Ontology (GO) annotation enrichment analysis for each category of bioUb hits. The heat map shows the
overrepresentation significance (log10 of the p value) of GO biological process terms across different categories. The blue lines highlight GO terms
specifically enriched in C-phase-specific hits, and the green line highlights those enriched in non-phase-specific hits.
TABLE I
Mitotic exit-specific ubiquitome
Protein name Posterior errorprobability (PEP) score
Peptide numbers C:M p value of C-phase
enrichmentExperiment 1 Experiment 2
Kinesin-like protein KIFC1 1.01E-78 7:2 13:0 0.000122
Lamin-B2 3.09E-45 9:2 16:1 0.0001373
Lamin-B1 5.65E-41 11:2 14:1 0.0004882
Rac GTPase-activating protein 1 3.17E-147 10:0 10:0 0.0009765
Cytoskeleton-associated protein 2 0.00066908 7:0 2:0 0.0078125
Signal recognition particle 54 kDa protein 4.01E-24 11:2 7:1 0.0112304
Prelamin-A/C 1.75E-26 6:1 10:2 0.0192871
Cytoskeleton-associated protein 2-like 0.012934 4:0 1:0 0.0625
Importin subunit -2 3.81E-20 4:0 2:0 0.0625
D-3-phosphoglycerate dehydrogenase 1.67E-05 3:0 3:1 0.125
Kinesin-like protein KIF11 0.00021216 3:0 2:0 0.125
Protein regulator of cytokinesis 1 6.59E-05 2:0 3:0 0.125
26S protease regulatory subunit 4 1.35E-12 1:0 4:1 0.1875
G2/mitotic-specific cyclin-B1 5.66E-08 2:0 2:0 0.25
Protein hits from bioUb-specific pulldowns, ranked according to their enrichment in C phase samples. Only top-ranked proteins identified in
two repeats of the experiment are included in the table. Peptide numbers from either C1 or C2 phase versus M phase samples are listed, and
a binomial test was used to calculate the significance of the C phase enrichment in peptide numbers. The lesser of the two calculated p values
is listed for each hit.
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in an in vivo ubiquitination assay to quantify the ubiquitin-
modified fraction of Venus-tagged proteins purified using
GFP-Trap® pulldown technology (57) from cells arrested in M
phase or released into C phase by Cdk1 inhibition. We found
that RacGAP1 ubiquitination could not be detected via this
method, as most of this protein was not extracted from the
C-phase nucleus under conditions optimized for GFP-Trap
pulldown (data not shown). However, we could readily mea-
sure the ubiquitination of KIFC1 and found it to be highly
C-phase specific and dependent on the APC/C (Fig. 4D). We
concluded that KIFC1 and RacGAP1 are both likely to be
direct substrates of APC/C-mediated proteolysis during mi-
totic exit and that, as has been found for several other char-
acterized substrates, they can be targeted by either Cdc20- or
Cdh1-activated APC/C.
New Functions for APC/C Targeting during Mitotic Exit—
We set out to investigate how the identification of KIFC1 and
RacGAP1 as substrates of the UPS at mitotic exit might add
to our understanding of mitotic exit control. We compared
wild-type and non-degradable Venus-tagged KIFC1 during
mitotic exit in live cells (supplemental Fig. S5). From late
anaphase onward, we found both wild-type and non-degrad-
able KIFC1-Venus were strongly localized at the spindle poles
and the central spindle. In cells expressing high levels of either
version of KIFC1-Venus, but not in cells expressing low levels,
the anaphase spindle was not correctly assembled, with re-
duced MT density in the central spindle relative to the spindle
poles (supplemental Fig. S5). These observations suggest
that control of KIFC1 levels is critical for correct regulation of
MT dynamics. Indeed, it has previously been shown that
ectopically expressed KIFC1 must be sequestered into the
nucleus during interphase to prevent inappropriate bundling
of cytoplasmic MTs during interphase (51). However, be-
cause the expression level of non-degradable KIFC1-Venus
was always higher than that of wild-type KIFC1-Venus (sup-
plemental Fig. S5), we were unable to draw conclusions
about any specific role for mitotic degradation of KIFC1.
Therefore, we focused our subsequent studies on
RacGAP1. As a key regulator of cytokinesis, RacGAP1 is
required to recruit and activate Ect2, the guanine nucleotide
exchange factor that activates RhoA to initiate contractile ring
assembly and constriction (58). Depletion of RacGAP1 causes
FIG. 3. Immunoblot validation of specific ubiquitin conjugates identified via mass spectrometry. A–C, loading in pulldown lanes 

1000 loading in input lanes, except for LMNB2 (700), UBE2R1 (700), and UBE2C (550). Ubiquitinated material in pulldowns appears
either as up-shifted monoubiquitinated bands (*) or as polyubiquitinated proteins in high-MW smears (indicated by arrows). E2 enzymes purified
as ubiquitin thiolester conjugates, which were reduced during elution because DTT was present, migrated at the same MW as the unmodified
protein (indicated by arrowheads). A, Cdc20 and PSMC5 (Sug1) were strongly polyubiquitinated in all fractions. B, mitotic regulators KIF11,
TPX2, AURKA, and KIFC1, as well as nuclear lamin LMNB2, were present as polyubiquitin conjugates specific to mitotic exit fractions. Where
input and eluate are shown in separate panels, the eluate panel was taken from a longer exposure of the same blot. See supplemental Fig. S3
for full-size blots and additional validations. Mono-ubiquitination of Aurora A (*) has not previously been described. C, E2 enzymes UBE2R1 and
UBE2C were strongly enriched in bioUb pulldowns, with UBE2C additionally polyubiquitinated late in mitotic exit (long exposure).
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extensive cytokinesis failure (59, 60). RacGAP1 additionally
plays a structural role in mediating interaction between the
spindle midzone and the cell membrane through its C1 lipid-
binding domain, an interaction that is required to maintain the
connection of the plasma membrane to the midbody following
furrow ingression, until abscission (61). The GAP activity of
RacGAP1 is not thought to play a critical role in contractile
ring assembly but is proposed to down-regulate Rac activity
at the cell equator to reduce cell adhesion and allow furrow
ingression (32). The corollary to this idea is that suppression of
RacGAP1 function outside of the equatorial region would be
required for the subsequent process of cell spreading that
requires Rac activity (32, 62). Therefore, we tested whether
ubiquitin-mediated proteolysis contributes to spatial regula-
tion of RacGAP1 during mitotic exit.
In support of the idea that RacGAP1 would be targeted for
proteolysis outside of the equatorial region of the cell, we
found that we could measure more rapid proteolysis of
Venus-RacGAP1 if we excluded the midbody from our anal-
ysis of degradation in single cells (supplemental Fig. S6).
However, our in vivo proteolysis assay relied on overex-
pressed RacGAP1 that may have been in excess relative to its
centralspindlin partner MKLP1. Because the available anti-
body against RacGAP1 did not allow us to measure levels of
the endogenous protein (because of nonspecific nuclear
staining), we tested instead for spatial regulation of proteoly-
sis of GFP-RacGAP1 in cell lines in which low-level expres-
sion of GFP-RacGAP1 complements siRNA-mediated knock-
down of the endogenous protein (61) (Fig. 5A). In this
experiment we measured RacGAP1 levels in late mitotic cells
after fixation and processing for immunofluorescence analy-
sis. We found that the ratio of RacGAP1 outside of the mid-
body was increased after treatment of cells with a proteasome
inhibitor, suggesting that RacGAP1 is preferentially targeted
for destruction outside of the midbody. We confirmed that
Venus-RacGAP11–52, which is unable to bind MKLP1 and
FIG. 4. KIFC1 and RacGAP1 are mitotic exit-specific APC/C substrates. A–B, Venus-tagged KIFC1 or RacGAP1 were electroporated into
U2OS cells, and after 12 to 24 h mitotic cells were imaged by means of fluorescence time-lapse microscopy. Venus levels in individual mitotic
cells were quantified and plotted as a function of anaphase onset. In vivo degradation curves are shown as averaged results with error bars
showing standard deviations. A, KIFC1-Venus is a substrate of mitotic-exit-specific proteolysis that depends on a putative D-box (R5xxL) in
the unstructured N terminus. B, Venus-RacGAP1 is a substrate of mitotic-exit-specific proteolysis, as a decrease in Venus-RacGAP1 levels did
not occur in cells treated at anaphase onset with 5 M MG132. See also supplemental Fig. S4. C, depletion of APC3 stabilizes endogenous
KIFC1 and RacGAP1 in mitotic exit. U2OS cells were transfected with siRNA against control (luciferase, GL2), APC3, or Cdh1 sequences,
synchronized to prometaphase as described in Fig. 1D and released using CDKI/II inhibitor. Cells were harvested at the indicated time points,
and whole cell lysate was examined via immunoblot with antibodies against known and putative APC/C substrates. APC3 immunoblot
indicated progress of mitotic exit with reversal of marked mitotic phosphorylation shift. D, in vivo ubiquitination of KIFC1-Venus was sensitive
to the depletion of APC3. KIFC1-Venus electroporated into bioUb cells synchronized in M and C phases as in C was subjected to GFP-Trap®
pulldown as described in Ref. 57. Anti-GFP immunoblot revealed unmodified KIFC1-Venus (in green), whereas anti-biotin immunoblot revealed
KIFC1-Venus-associated ubiquitin conjugates (in red).
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FIG. 5. APC/C suppresses cytoplasmic RacGAP1 to promote cell spreading after mitosis. A, RacGAP1-GFP is targeted for proteolysis
outside of the midbody. Cells expressing low levels of RacGAP1-GFP and in which endogenous RacGAP1 was depleted by siRNA for 48 h were
fixed after 15 min of treatment with 5 M MG132 and stained with GFP antibody. Fluorescence intensities in cells undergoing mitotic exit were
quantified and expressed as the ratio of total fluorescence in cytoplasm (non-midbody) versus midbody. Arrowheads indicate midbodies of
cells where cytoplasmic GFP staining was not visible. Scale bar
 20 m. B, fluorescence time-lapse images of cells expressing Venus-tagged
RacGAP1 show that whereas in low-expressing cells all RacGAP1 was visible in the midbody (arrowheads), in high-expressing cells excess
protein was clearly visible on the polar cell cortex (arrows) and in the nucleus. Scale bar 
 10 m. C, lysine residue K292 mediates
mitotic-exit-specific polyubiquitination on RacGAP1. bioUb cells were electroporated with indicated Venus-RacGAP1 constructs and synchro-
nized to M phase or C2 phase as described in Fig. 1D. Ubiquitinated proteins were purified via NeutrAvidin pulldown and probed with GFP
antibody (that recognized the Venus tag). C, 599–632. D, K292 mediates mitotic-exit-specific proteolysis of RacGAP1. Degradation of
Venus-tagged RacGAP1 wild-type or K292R or K292R,K296R (2KR) mutant was measured as described in Fig. 4B. E, non-degradable
RacGAP1 interfered with cell spreading after mitosis. mCherry-tagged RacGAP1 was electroporated into RPE -actinin-Venus cells. After 8 to
20 h cells were imaged via fluorescence time-lapse microscopy. Cell area was visualized by -actinin-Venus signal, measured at 10-min time
intervals during mitotic exit and normalized to the cell area at metaphase for each cell. Spreading curves of individual cells (bottom panel) are
averaged results with error bars to show standard deviations. Student’s t test of cell spreading at the 70-min time point showed that the delay
in the presence of K292R was significant (p 
 0.0016), whereas in F289G it was not (p 
 0.44). Scale bar in E 
 20 m.
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therefore defective in midbody localization (60, 61), was de-
graded more rapidly than Venus-RacGAP1-WT, and that
overexpression of mCherry-MKLP1 conferred stabilization of
Venus-RacGAP1, most dramatically at later time points during
mitotic exit (supplemental Fig. S6). We concluded that incor-
poration of RacGAP1 into centralspindlin protects this pool
from APC/C-mediated degradation.
RacGAP1 Ubiquitination Contributes to Cell Spreading after
Mitosis—From these results we formed the idea that APC/C
activity “titrates” RacGAP1 levels to ensure that all non-
MKLP1-bound RacGAP1 is removed from the cytoplasm dur-
ing mitotic exit. Our movies of Venus-RacGAP1 indicated that
overexpressed protein was ectopically recruited to the cell
cortex and associated with persistent contractility and bleb-
bing (Fig. 5B, supplemental Movies S1 and S2) in a manner
incompatible with post-mitotic cell spreading and in line with
previous work showing that Drosophila RacGAP1 deliberately
targeted to the cell cortex outside of the equatorial region
promotes widespread ectopic furrowing (63). Therefore we
reasoned that APC/C-mediated targeting of RacGAP1 would
contribute to relaxation of the polar cortex for cell spreading
after mitosis.
We wanted to test this hypothesis by generating a non-
degradable version of RacGAP1. Inspection of proteomic da-
tasets revealed that one ubiquitinated peptide (containing
lysines K292 and K296) appears more frequently than any
other (22–24, 26, 28), and moreover K292 is present in a
context that fits our recently published description of APC/C
ubiquitination site flanking region preferences with a serine at
the -1 position (57). We mutated these lysines and confirmed
that Venus-RacGAP1-K292R shows strongly reduced ubiq-
uitination in mitotic exit (Fig. 5C) and that both lysines K292
and K296 contribute to in vivo destruction of RacGAP1 during
mitotic exit (Fig. 5D). Because K292 has also been shown to
be essential for the function of the RacGAP1 C1 domain in
binding to the plasma membrane, we also tested a second C1
domain mutant, Venus-RacGAP1-F289G (61). This version
was ubiquitinated as efficiently as wild-type Venus-RacGAP1,
confirming that reduced ubiquitination of Venus-RacGAP1-
K292R in vivo was not the result of altered RacGAP1 topology
at the plasma membrane (Fig. 5C).
During the preparation of this manuscript, a newly pub-
lished study described an APC/C-dependent degron for
RacGAP1 in its C-terminal region (56). Our own study showed
that a C-terminal truncation did reduce mitotic ubiquitination
of RacGAP1 (Fig. 5C). However, we also found that when
tagged with GFP, this version of RacGAP1 did not localize like
the wild-type protein.3 Therefore, we confined our subsequent
studies to the non-ubiquitinable version of RacGAP1 gener-
ated by mutating ubiquitin acceptor lysine K292.
We then compared cell spreading in cells expressing wild-
type and non-ubiquitinable versions of mCherry-RacGAP1
using hTERT-RPE -actinin-Venus cells in which cell spread-
ing can readily be visualized and quantified (33). Cells elec-
troporated with RacGAP1 constructs were recorded through
mitosis by means of fluorescence time-lapse imaging, and the
areas of daughter cells, normalized for the area at metaphase,
were plotted against time. We found that the expression of
wild-type mCherry-RacGAP1 had no effect on cell spreading
relative to that in non-mCherry expressing control cells,
whereas cell spreading was significantly defective in cells
expressing mCherry-RacGAP1-K292R but not in cells ex-
pressing mCherry-RacGAP1-F289G (Fig. 5E; supplemental
Movies S3 and S4). These results are consistent with our
proposed model that delay in cell spreading is a conse-
quence of reduced ubiquitin-mediated degradation of
RacGAP1 (Fig. 6).
Novel Roles for the APC/C and Other Ubiquitin Ligases in
Mitotic Exit Pathways—Having validated our mitotic-exit-spe-
cific hits KIFC1 and RacGAP1 as bona fide APC/C substrates
contributing to mitotic exit, we then asked how many of our
other 170 mitotic-exit-specific hits could be APC/C sub-
3 M. Min and C. Lindon, unpublished data.
FIG. 6. A model for spatial regulation of RacGAP1 by APC/C-mediated ubiquitination. Most RacGAP1 is recruited to the midbody as a
heterotetrameric complex with MKLP1, where it recruits ECT and suppresses Rac1 activity to bring about cleavage furrow ingression. Any
non-midbody-associated RacGAP1 can potentially interfere with cytokinesis through inappropriate recruitment of ECT2 or suppression of Rac1
(32, 63) and is targeted for ubiquitination on K292 by the APC/C.
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strates. We compared the enrichment of APC/C degrons (D-
box and KEN box) in our list of hits and in a list compiled from
validated APC/C substrates (57). We found very strong en-
richment for both types of motifs in the list of known APC/C
substrates, as well as significant enrichment in our experi-
mental dataset (Fig. 7A). From this analysis we estimated that
one-quarter of our hits could be new APC/C substrates. How-
ever, given that non-canonical degrons have been identified in
several APC/C substrates (3), it is possible that our dataset
includes many more such APC/C substrates that lack D-
boxes or KEN motifs. Alternatively, our result might indicate a
role for other ubiquitin ligases in mitotic-exit-specific ubiquiti-
nation. Indeed, our purification of E2 enzymes and HECT-type
E3 ligases specifically from the mitotic exit fractions suggests
the activity of novel ubiquitination pathways at this point of the
cell cycle (supplemental Table S3).
Finally, we searched our mitotic exit ubiquitome using
PSICQUIC (64) for protein interactions that might indicate
cellular processes regulated by ubiquitination during mitotic
exit. As expected, one prominent cluster was the mitotic
FIG. 7. Ubiquitination of cellular components during mitotic exit. A, enrichment analysis of the D-box and the KEN box in mitotic-exit-
specific hits compared with non-phase-specific hits and a dataset of known APC/C substrates curated from the literature (57). The sequence
of each protein was scanned for the presence of potential D-box (RXXL) and KEN motifs. The significance of enrichments was plotted as
log10(p values) calculated using a binomial test (null hypothesis: the frequency of observing D-box and KEN degrons is not greater in our
dataset than in the whole human proteome) and indicated the presence of new APC/C substrates in our dataset, as even after removing known
APC/C substrates from our dataset of mitotic-exit-specific hits we observed enrichment of degrons relative to the nonspecific dataset. B,
interactions among proteins specifically ubiquitinated during mitotic exit. Protein interaction data were obtained using PSICQUIC (64) and
plotted using Cytoscape (71).
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machinery, many components of which are known targets of
APC/C-mediated proteolysis after mitosis. We also found
other hits clustering to organelles known to undergo mitosis-
specific regulatory processes, such as the nuclear envelope
and the ribosome (65, 66) (Fig. 7B). We concluded that wide-
spread ubiquitination of cellular components during mitotic
exit contributes to the extensive reorganization required for
the mitosis–interphase transition.
DISCUSSION
We have presented for the first time a ubiquitinated pro-
teome from mammalian cells that contains cell cycle phase-
specific information. Our identification of a large number of
UPS substrates targeted specifically during mitotic exit, and
even at specific times during mitotic exit (for example, Aurora
A, Lamin B2), indicates the wealth of information that can be
gathered from using synchronized cell populations. Indeed,
17 of our mitotic-exit-specific hits had never been identified
as in vivo ubiquitinated proteins before, including APC/C sub-
strates anillin, sororin, and TOME-1. This suggests that our
highly synchronized samples enabled the identification of rare
ubiquitinated substrates whose ubiquitination only happens
at a specific moment in the cell cycle.
Our proteomic strategy based on the purification of intact
ubiquitinated material allowed us to validate 100% of our
candidate ubiquitinated proteins using immunoblotting with
substrate-specific antibodies. This validation strategy pro-
vided significantly more information about identified ubiquitin
conjugates than available from diGly-based proteomics, for
example, by revealing the dramatic switch from mono- to
(monopoly)-ubiquitinated Aurora A kinase that occurs be-
tween C1 and C2 phases (Fig. 3B), a switch likely to be of
biological significance. Unlike diGly-based proteomics, how-
ever, our strategy did not find many sites of ubiquitination on
individual substrates (that is, only a small fraction of assigned
peptides contained diGly- modified lysine residues). This limi-
tation in our strategy could reflect a pattern of mitotic poly-
ubiquitination on multiple adjacent lysine residues, a situation
that precludes identification by mass spectrometry, or it could
simply result from the complexity of the purified material
presenting a challenge for analysis by mass spectrometry.
Indeed, the peptide coverage of most substrates identified,
including several of those that we subsequently validated,
was very low. Future studies in which bioUb purification could
be combined with a diGly purification step to (a) reduce the
complexity of the samples and (b) identify ubiquitinated lysine
residues would provide a valuable further resource for the
investigation of substrate ubiquitination.
Our strategy also provided quantitative comparisons of the
fraction of modified substrates and the extent of modification,
enabling us to identify Cdc20, spartin, and PSMC5 as sub-
strates with very high polyubiquitinated fractions. In the case
of Cdc20, polyubiquitination plays a crucial function in SAC
signaling (67), and we can speculate that spartin and
PSMC5 might also require functionally significant constitu-
tive polyubiquitination. Multiple monoubiquitination of spar-
tin has previously been described (68). The same study
identified potential K48-dependent polyubiquitination of
spartin, but no functional significance has yet been attached
to this modification.
We believe our two overlapping datasets identify a signifi-
cant fraction of the mitotic polyubiquitinated proteome, al-
though the absence of some critical APC/C substrates (such
as securin) indicates that they are not complete. This could
reflect the complexity of the purified material, as discussed
above, or the fact that we did not treat cells with proteasome
inhibitors, as is commonly done to enrich ubiquitinated ma-
terial destined for degradation. We avoided conditions of
proteasome inhibition because we wanted a global view of
mitotic exit ubiquitination that would include non-degradative
ubiquitination events. Proteasome inhibition can also give rise
to stress-induced changes to UPS function (69).
A significant fraction of proteins specifically ubiquitinated in
mitotic exit are likely to be substrates of the APC/C (and
destined for the 26S proteasome). Indeed, the candidate hits
that we selected for further study, kinesin 14 family member
KIFC1 and centralspindlin component RacGAP1, were two
such substrates. However, the enrichment of typical APC/C
degron motifs in our mitotic exit ubiquitinated proteome was
less than in the list of known APC/C substrates, indicating
potential roles for other ubiquitin ligases in mitotic-exit-spe-
cific ubiquitination. Indeed, preliminary investigations of our
novel targets of mitotic-exit-specific ubiquitination showed
that some were not significantly degraded during mitotic exit,4
indicating roles for non-degradative ubiquitination. Our assay
could be developed to test the roles of other ubiquitin ligases
during mitotic exit.
We investigated further why RacGAP1 would be targeted to
the 26S proteasome specifically during mitotic exit. Our find-
ings indicated that any RacGAP1 not localized to the midbody
(where it is required for different steps in cytokinesis) be-
comes a target for the APC/C after anaphase onset, and
therefore APC/C-mediated targeting of RacGAP1 contributes
to its exclusive localization at the equatorial region of cells
exiting mitosis. Further studies with a stabilized version of
RacGAP1 confirmed our hypothesis that ubiquitination of
RacGAP1 in daughter cells is required for normal cell spread-
ing as cells return to interphase. These results are consistent
with the observation that Rac1 activity after telophase is in-
creased in the polar regions of dividing cells (62), where it can
be predicted to play critical roles in cell spreading via effectors
that regulate actin dynamics (70). Cell spreading is just one of
the major reorganizations of the cell that occurs at this time.
The hits from our study generated functional clusters indicat-
ing some of the processes regulated by ubiquitination during
mitotic exit—in particular via the proteasome lid, nuclear
4 S. Wood, M. Min, and C. Lindon, unpublished data.
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lamins, and mitotic spindle machinery—that remain to be
explored in further detail.
In conclusion, we have described an important novel re-
source, human cells expressing in vivo–biotinylatable ubiqui-
tin, than can be applied to the problem of identifying and
quantifying endogenous polyubiquitinated targets of the UPS.
In this study we used bioUb cells to elucidate the mitotic exit
ubiquitome, thus furthering our understanding of UPS-medi-
ated events regulating the assembly of daughter cells after
mitosis.
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